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Abstract
Introduction: The aim of the study was to evaluate the correlation between the presence of anti-C. trachomatis (C.t.) anti-
bodies in serum and expressed prostatic secretions (EPS) and the concentration of citric acid in patients with chronic pro-
statitis.
Materials and Methods: The study involved 34 men with chronic prostatitis. The leukocyte count, presence of anti-C.t. anti-
bodies (IgA, IgG), and citric acid concentration were determined in the EPS. The serum was examined for IgM, IgA, and
IgG anti-C.t. antibodies. Specific antibodies were determined using the EIA method. The concentration of citric acid was
measured using the ultraviolet method.
Results: Inflammation of the prostate (≥10 PMN) was found in 61.8% of the patients. A reduction in citric acid concentra-
tion in the EPS was detected in 58.8% of the men. Specific serum antibodies were detected in 58.8% of the patients, includ-
ing 23.5% with IgM, 32.4% with IgA, and 44.1% with IgG. In all patients, serum IgM and IgA antibody titers were low, while
those of IgG antibodies were strongly positive in 46.7% of the patients. Anti-C.t. antibodies in the EPS were detected in
44.1% of the patients, including 32.4% with IgA and 35.3% with IgG. In contrast to serum, the titers of IgG antibodies in
the EPS were low in all the patients, while those of IgA were strongly positive in 54.5% of cases. In patients with positive
serological outcomes, 85% had reduced concentrations of citric acid.
Conclusions: The occurrence of anti-C.t. antibodies is usually accompanied by a decrease in the concentration of citric acid
in the prostatic secretion.
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ORIGINAL ARTICLE
INTRODUCTION
Chlamydia trachomatis (C. trachomatis) is a major
sexually transmitted bacterial pathogen [1]. Since
chlamydial infections are usually asymptomatic or
oligosymptomatic, they are difficult to diagnose and
may thus lead to serious sequels. One of the complica-
tions of C. trachomatis infection in men is chronic pro-
statitis [15, 22, 24]. The concentration of citric acid,
which is produced and stored in the prostate in great
amounts, can be regarded as an indicator of the normal
functioning of the prostate [2, 6]. When the function is
impaired, e.g. due to prostatitis, the concentration of cit-
ric acid is reduced [2, 7].
The aim of this study was to evaluate the correlation
between the presence of anti-C. trachomatis antibodies
in the serum and prostatic secretion and the concentra-
tion of citric acid in patients with chronic prostatitis.
MATERIALS AND METHODS
The study involved 34 men aged 18–65 years (mean:
38 years) with chronic prostatitis referred to the Center
for Sexually Transmitted Disease Research and
Diagnostics in Bia³ystok by urological consulting units.
These patients belonged to group III according to the
National Institutes of Health (NIH) prostatitis classifi-cation of 1995, which is chronic prostatitis/chronic pelvic
pain syndrome [15]. None of the patients had been
treated with antibiotics for at least three months before
the study.
Expressed prostatic secretions (EPS) and blood
serum were used as the material for analysis. The poly-
morphonuclear leukocyte (PMN) count, the presence of
anti-C. trachomatis antibodies (IgA and IgG), and citric
acid concentration were determined in the prostatic
secretion. The serum was examined for IgM, IgA, and
IgG class anti-C. trachomatis antibodies.
A drop of EPS was used to make a direct prepara-
tion on a glass slide. After fixation and staining by
means of Gram’s method, leukocytes were counted.
Inflammation of the prostate was diagnosed when the
PMN count was ≥10 in the visual field under a light
microscope with a magnification of ×1000.
The anti-C. trachomatis antibodies were determined
using the immunoenzymatic method. Specific IgG anti-
bodies were identified in the serum by means of
Chlamydia IgG EIA (Labsystem, Finland) and serum
IgM+IgA and IgG+IgA in the EPS with Chlamydia
rELISA (Medac, Germany). In the tests performed
using the Labsystem kit, according to the manufactur-
er’s instructions a value of ≥20 enzyme immunoassay
unit (EIU) was considered positive (<10 EIU: negative,
10–19 EIU: equivocal, 20–59 EIU: weakly positive,
60–110 EIU: positive, >110 EIU: strongly positive).
With the Medac kit, titers equal to or greater than 1:100
(IgG antibodies) and 1:50 (IgM and IgA antibodies)
were treated as positive.
The concentration of citric acid was determined at
the Department of Medical Biochemistry, Medical
University of Bia³ystok, using the ultraviolet method
(TC Citric Acid, Boehringer, Germany) [23]. A concen-
tration of 18.84±0.72 mg/ml (18.12–19.59 mg/ml) was
treated as normal [5].
This study was approved by the University Ethics
Committee.
RESULTS
Inflammation of the prostate was found in 21/34
(61.8%) patients. A reduction in citric acid concentra-
tion in the prostatic secretion was detected in 20/34
(58.8%) men. In most patients (17/20, 85%), the
reduced citric acid concentration was accompanied by
an elevated PMN count in the EPS (≥10/vision field).
Specific serum antibodies were detected in 20/34
(58.8%) patients, including IgM in 8/34 (23.5%), IgA in
11/34 (32.4%), and IgG in 15/34 (44.1%; Fig. 1). All the
patients showed low titers of IgM and IgA antibodies in
the serum and 7/15 (46.7%) patients had strongly posi-
tive IgG antibodies. In 11/15 (73.3%) patients, the spe-
cific IgG antibodies in the serum occurred together with
IgM and/or IgA antibodies, and were found isolated in
the remaining 4/15 (26.7%) cases. Table 1 presents a list
of positive serological outcomes according to the
immunoglobulin classes. The synergistic occurrence of
IgG and IgA was the most common (35%), the isolated
occurrence of IgG antibodies was less common (20%),
and of IgA the least common (5%).
The anti-C. trachomatis antibodies in the EPS were
detected in 15/34 (44.1%) patients, including 11/34
(32.4%) with IgA and 12/34 (35.3%) with IgG (Fig. 2).
In contrast to serum, the titers of IgG antibodies in the
EPS were low in all the patients, while those of IgA were
strongly positive in 6/11 (54.5%) patients. Table 2 pre-
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Fig. 1. The rate of detection of anti-C. trachomatis antibodies in
the serum in chronic prostatitis patients.
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Table 1. Co-occurrence of anti-C.trachomatis antibodies
according to immunoglobulin class in a group of 20 patients
with serum-positive serological outcomes
Class of immunoglobulin  Patients with serum-positive
anti-C. trachomatis serological outcomes (N=20)
antibodies in serum n%
IgM 2 10
IgA 1 5
IgG 4 20
IgG+IgM 2 10
IgG+IgA 7 35
IgM+IgA 2 10
IgG+IgM+IgA 2 10
Total 20 100
Fig. 2. The rate of detection of anti-C. trachomatis antibodies in
the EPS in chronic prostatitis.
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35.3sents the serum antibodies of the respective classes in
the EPS. The co-occurrence of IgA and IgG (53.3%)
was the most frequent, isolated IgG antibodies were less
common (26.7%), and isolated class IgA the least com-
mon (20%).
In the group of 20 patients with positive serum
and/or EPS outcomes, 17 (85%) had reduced concen-
trations of citric acid (Table 3). In the majority of
patients with reduced citric acid concentration in the
EPS (16/17, 94.1%), anti-C. trachomatis antibodies were
present both in the serum and EPS. The greatest decline
in the concentration of citric acid was observed in men
showing remarkably high titers of IgA antibodies in the
EPS and/or IgG in the serum.
DISCUSSION
Prostatitis, a major sequel of C. trachomatis urethri-
tis in men, is usually chronic and oligosymptomatic [17].
The bacteriological diagnostics of prostatitis is very dif-
ficult, mainly due to the poor availability of adequate
material and the difficult choice of a proper method
[21]. Fundamental methods in diagnosing chlamydial
infections are direct methods that detect bacterial anti-
gens (DIF, i.e. the direct immunfluorescence test, and
EIA), genetic material (PCR, i.e. polymerase chain
reaction, LCR, i.e. ligase chain reaction), or, currently
rarely performed, culture methods. The role of serodi-
agnostics using both serum and prostatic secretion has
been emphasized in literature, especially because of the
non-invasive nature of the method and the easy avail-
ability of the material [18]. There are only a few studies
concerning the problem of chlamydial prostatitis com-
bined with determining citric acid concentration.
In our study, serum IgG antibodies were the most
frequently detected (44.1%), IgA antibodies were less,
and IgM the least common (32.4% and 23.5%, respec-
tively). In all cases the titers of IgA and IgM antibodies
were low, while those of IgG were high in nearly half of
the patients (46.7%). Similar or higher values of IgG
antibodies were noted by Weidner et al. [20] (40.5%)
and Peeters et al. [16] (49%), but lower were reported
by Kojima et al. [9] (7.5%) and Miyata et al. [14] (29%).
High titers of specific IgG antibodies as well as the pres-
ence of IgA antibodies in the serum provide evidence
for an active, Chlamydia-induced pathological process.
The role of IgM antibodies in the diagnostics of chronic
prostatitis is slight, as they can be detected only in the
very early phase of infection and are thus rarely found in
men with chronic prostatitis [4, 12].
We found specific IgG antibodies in the prostatic
secretion in 35.3% of the men and IgA in 32.4%.
Contrary to the serum, the values of IgA antibodies in
the EPS were considerably higher than the titers of IgG
antibodies. In all the patients, the presence of specific
antibodies in the EPS was accompanied by anti-C. tra-
chomatis antibodies in the serum and elevated EPS
leukocyte count. Similar results concerning IgA anti-
bodies were reported by Japanese authors, who found
them in the prostatic secretion in 31.5% [13] and 29%
[10] of men. High titers of IgA antibodies and increased
PMN counts detected in the EPS indicate stimulation of
the local immunological response by resident microor-
ganisms. Tsunekawa et al. [18, 19] also observed high
titers of IgA and low titers of IgG in the EPS compared
with serum. Ludwig et al. [11] considered the determi-
nation of anti-C. trachomatis antibodies in serum unser-
viceable in diagnosing chlamydial infection, while the
role of antibodies in semen, especially the IgA class, is
still unclear and needs further investigation. The
authors revealed in their study significant correlation
only between seminal plasma antibodies against C. tra-
chomatis and positive PCR results in the ejaculate. In
our study, the level of IgA antibodies in the EPS was
particularly high, in contrast to the serum level.
The role of antichlamydial antibodies in C. tra-
chomatis infection is still controversial. However, it is
still believed that antibody marking may be important in
detecting the spread of chronic urogenital tract infec-
tions on the ascending path from the urethra or cervix
and its remote complications, such as epididymitis, pro-
statitis, pelvic inflammatory disease, or infertility. 
In most patients (85%) with specific antibodies
detected in the serum or/and EPS there was a simulta-
neous decrease in the concentration of citric acid in the
prostatic secretion. The prostate is the major site of pro-
duction and the largest reservoir of citric acid in the
organism [3, 6]. The level of citric acid decreases in
inflammatory conditions of the prostate and in other
diseases that impair the functioning of the gland [2, 8].
I. Ostaszewska−Puchalska et al.: C. trachomatis antibodies in prostatitis 59
Table 2. Co-occurrence of anti-C. trachomatis antibodies
according to immunoglobulin class in a group of 15 patients
with EPS-positive serological outcomes
Class of immunoglobulin  Patients with EPS-positive
anti-C. trachomatis serological outcomes (N=15)
antibodies in the EPS n%
IgA 3 20
IgG 4 26.7
IgG+IgA 8 53.3
Total 15 100
Table 3. Correlation of occurrence of anti-C. trachomatis
antibodies in serum or/and EPS with citric acid concentration
in the prostatic secretion
Concentration  
Patients with positive serological
Total
of citric acid 
outcomes (N=20)
(%)
in EPS
only only in  EPS
in EPS in serum and in serum
n (%) n (%) n (%)
Decreased 0 1 (5) 16 (80) 17 (85)
No changes 0 3 (15) 0 3 (15)
Total 0 4 (20) 16 (80) 20 (100)A reduced concentration of citric acid in patients with
detected infection of C. trachomatis suggests the exis-
tence of prostatitis induced by Chlamydia. In an earlier
study we conducted research in the same group of
patients evaluating the relationship between chlamydial
prostatitis detected by means of direct tests (DIF, PCR)
and citric acid concentration in the prostate gland [25].
We found that chlamydial infection of the prostate coex-
isted in all cases with a reduced concentration of citric
acid, in most of the cases significantly. No literature
reports are available on the relationship between the
detection of anti-C. trachomatis antibodies in the serum
and/or EPS and the concentration of citric acid in the
EPS.
In conclusion, 1) the occurrence of anti-C. tra-
chomatis antibodies in the serum and/or EPS in most
patients is accompanied by a decrease in the concentra-
tion of citric acid in the prostatic secretion, suggesting
functional impairment of the gland; 2) serological inves-
tigations of the serum and EPS for chlamydial infection
can be treated as a supplementary, non-invasive method
in the diagnostics of chronic prostatitis.
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